This U.S. patent brings additional protection to Flow Pharma's Size Exclusion Antigen Presentation Control SEAPACTM vaccine technology
NEWARK, CA / ACCESSWIRE / January 8, 2019 / Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing its FlowVax peptide vaccine platform technology, today announced that it has received patent number 10,172,936 from The United States Patent and Trademark Office (USPTO). This patent is part of Flow Pharma's growing family of peptide vaccine platform patents.
The FlowVax vaccine platform is a synthetic, room temperature, stable, dry powder readily programable at the time of manufacture to target cancer cells of individual patients. Each of the individual components used in the FlowVax vaccine platform part of various FDA approved vaccines and pharmaceuticals developed by other companies. Flow Pharma has been manufacturing FlowVax vaccines for pre-clinical testing at its facility in Newark California and plans to begin clinical trials for FlowVax HPV to treat women with cervical cancer later this year.
"The patent issued to Flow Pharma today further strengthens their IP position beyond patents already issued in Australia, Canada, the United States and the European Union. The Company's evolving patent portfolio provides a high degree of market exclusivity around Flow Pharma's FlowVax vaccine platform" said Karl Bozicevic, J.D., LL.M., senior partner with the patent law firm Bozicevic, Field & Francis, LLP.
"Personalized cancer vaccine therapy must be manufactured quickly while creating a reliable immune response to multiple targets on cancer cells. The FlowVax platform allows a new vaccine to be quickly deployed. Multiple pre-clinical tests have shown that FlowVax produces a safe and reliable immune response in mice" said Charles Herst, Ph.D., Flow Pharma's Chief Science Officer.
"We have spent 10 years developing our FlowVax vaccine platform. We believe it is ideally suited for immunizing patients to target tumor-specific neoantigens with their killer T-cells. Our proprietary manufacturing process makes FlowVax microspheres the same size as white blood cells, allowing each white blood cell to process only one neoantigen at a time optimizing the critical antigen presentation process. We call this approach Size Exclusion Antigen Presentation Control, or SEAPAC for short. This concept is protected by the patent issuing today as well as other of our patents issued and pending" said Reid Rubsamen, M.D., co-inventor of the patent issuing today and CEO of Flow Pharma.
About Flow Pharma
Flow Pharma, Inc. is a San Francisco Bay Area based, pre-clinical stage biotechnology company using artificial intelligence to guide selection of neoantigen peptide targets on cancer cells or virus-infected cells for attack by the patient's own, native immune system. These peptides can then be loaded into the FlowVax platform for administration by injection.
Flow Pharma, Inc. is preparing to test therapeutic cancer vaccines targeting neoantigens found in various cancers. Neoantigens are small peptide markers expressed on cancer cells as a result of a cancer-causing viral infection or mutation of the DNA in normal cells, agents that cause transformation into cancer cells.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. ("the Company"), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.
Media ContactInvestor Relations
Flow Pharma, Inc.
39655 Eureka Drive
Newark, California 94560
760-564-7400
www.flowpharma.com
[email protected]
SOURCE: Flow Pharma, Inc.